Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 461 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Amyotrophic Lateral Sclerosis (ALS) Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Early NIPPV, Standard NIPPV; Device
Lead sponsor: Edward Kasaraskis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 12
States / cities: Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more

Conditions: Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Radiculopathy, Myopathy, Polyneuropathy and Mononeuropathies, Trauma Injury, Orthopedic Disorder
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS), locked-in Syndrome, Brain Injury, Stroke
Interventions: RECLAIM System; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 22 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Listener judgements of speech produced in different tasks; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: ALS
Interventions: remote pulmonary function testing, standard pulmonary function testing; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 20 Years to 85 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK-2017357, Placebo tablets, Riluzole; Drug · Other
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 44
States / cities: Phoenix, Arizona • La Jolla, California • Orange, California + 38 more

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Edaravone (Radicava®/Radicava ORS®); Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 14 more

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Motor Neuron Disease, Familial
Interventions: Rehabilitation; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson Disease
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AP-101, Placebo; Drug
Lead sponsor: AL-S Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Brainstem Stroke, Paralysis, Brain-computer Interface, BCI
Interventions: Mind Extender (MindEx); Device
Lead sponsor: Nader Pouratian; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Tazbentetol; Drug
Lead sponsor: Spinogenix; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 16
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more

Conditions: ALS, Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CNM-Au8; Drug
Lead sponsor: Clene Nanomedicine; Industry
Eligibility: 18 Years and older
U.S. locations: 16
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 13 more

Conditions: Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sherman Oaks, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions: Intravenous and Intranasal BMSC; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BiPAP® S/T System, sham-NIPPV; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Levosimendan; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Phoenix, Arizona • La Jolla, California • Orange, California + 23 more

Conditions: Amyotrophic Lateral Sclerosis, Caregiver Burden
Interventions: Mindfulness, Mindful Learning; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Search by objective public record fields.

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

Innovative Ultrasound Technology in Neuromuscular Disease

REstoration of Communication and LAnguage With Intracortical Microelectrodes

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Assessing Perceptual Effects of Interactive Tasks

Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)

Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Rehabilitation and Exercise in SOD1-ALS TOfersen REcipients (RESTORE)

Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

Intermediate-size Patient Population Expanded Access Protocol

Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)

Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Neurologic Stem Cell Treatment Study

Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

A Mindful Community for People With ALS and Their Primary Caregivers